New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
10:02 EDTTDC, SREV, SKM, KBW, HME, ESRX, ENR, BMRN, AT, ASEIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Science & Engineering (ASEI) downgraded to Hold from Buy at Benchmark Co.... Atlantic Power (AT) downgraded to Hold from Buy at Desjardins... BioMarin (BMRN) downgraded to Hold from Buy at Brean Capital... Energizer (ENR) downgraded to Market Perform from Outperform at Bernstein... Express Scripts (ESRX) downgraded to Hold from Buy at Jefferies... Home Properties (HME) downgraded to Underperform from Sector Perform at RBC Capital... KBW, Inc. (KBW) downgraded to Market Perform from Outperform at JMP Securities... SK Telecom (SKM) downgraded to Neutral from Outperform at Credit Suisse... ServiceSource (SREV) downgraded to Equal Weight from Overweight at Morgan Stanley... Teradata (TDC) downgraded to Sector Perform from Outperform at FBN Securities.
News For ASEI;AT;BMRN;ENR;ESRX;HME;KBW;SKM;SREV;TDC From The Last 14 Days
Check below for free stories on ASEI;AT;BMRN;ENR;ESRX;HME;KBW;SKM;SREV;TDC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
09:04 EDTESRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:11 EDTENREnergizer expects Q4 organic net sales to be flat
Subscribe for More Information
07:09 EDTENREnergizer reaffirms FY14 adjusted EPS outlook $7.00-$7.25, consensus $7.08
Total company organic net sales are expected to decline in the low- to mid-single digits for FY14. Gross restructuring savings are expected to increase approximately $135M-$150M for FY14 versus the prior year; resulting in total estimated project to date savings of $235M-$250M.
07:07 EDTENREnergizer reports Q3 adjusted EPS $1.46, consensus $1.55
Subscribe for More Information
July 29, 2014
16:32 EDTESRXExpress Scripts sees FY15 retention rate 92%-93%
Subscribe for More Information
16:30 EDTESRXExpress Scripts reports Q2 adjusted claims 324.5M
Subscribe for More Information
16:30 EDTESRXExpress Scripts sees Q3 adjusted EPS $1.27-$1.31, consensus $1.29
Subscribe for More Information
16:28 EDTESRXExpress Scripts narrows FY14 EPS view to $4.84-$4.92 from $4.82-$4.94
Consensus $4.86.
16:27 EDTESRXExpress Scripts reports Q2 adjusted EPS $1.23, consensus $1.22
Reports Q2 revenue $25.11B, consensus $24.38B.
15:53 EDTENRNotable companies reporting before tomorrow's open
Subscribe for More Information
15:53 EDTESRXNotable companies reporting after market close
Subscribe for More Information
07:55 EDTESRXLeerink a buyer of Catamaran ahead of Q2 results
Leerink says it's a buyer of Catamaran (CTRX) ahead of the company's Q2 results as it believes shares have more room to run. The firm is cautious on Express Scripts (ESRX) after hearing from a specialist that service challenges may impact the company's 2015 and 2016 selling seasons. The firm remains positive on CVS Caremark (CVS), but notes shares have outperformed and the company could see retail pressure from recent drug inflation trends.
July 28, 2014
12:21 EDTESRXOn The Fly: Midday Wrap
Subscribe for More Information
10:26 EDTESRXExpress Scripts August weekly volatility elevated into Q2 and outlook
Subscribe for More Information
06:22 EDTESRXHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Subscribe for More Information
July 23, 2014
09:30 EDTESRXExpress Scripts downgraded to Neutral from Buy at Cleveland Research
Subscribe for More Information
08:10 EDTBMRNBioMarin, Sarah Cannon Research UK collaborate on EMBRACA clinical study
BioMarin Pharmaceutical and Sarah Cannon Research UK announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation. This ongoing Phase 3 trial has recently been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the United States, expanding the trial internationally.
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Subscribe for More Information
July 22, 2014
08:18 EDTTDCTeradata acquires assets of Revelytix and Hadapt
Subscribe for More Information
July 20, 2014
11:58 EDTTDCCaterpillar, five others should benefit from global recovery, Barron's says
Caterpillar (CAT), Teradata (TDC), Kennametal (KMT), Capital One Financial (COF), T. Rowe Price Group (TROW), and Chesapeake Energy (CHK) are all relatively cheap and should benefit from global recovery, Barron's contends in its cover article. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use